gefitinib has been researched along with thapsigargin in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (thapsigargin) | Trials (thapsigargin) | Recent Studies (post-2010) (thapsigargin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 5,234 | 3 | 918 |
| Protein | Taxonomy | gefitinib (IC50) | thapsigargin (IC50) |
|---|---|---|---|
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | Oryctolagus cuniculus (rabbit) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berry, CT; Brady, DC; Davis, CI; Feng, Z; Freedman, BD; Glynn, RA; He, X; Hua, X; Katona, BW; Liu, Y; Ma, J; Matkar, S; Paulosky, KE; Szigety, KM; Wang, H; Wu, Y | 1 |
1 other study(ies) available for gefitinib and thapsigargin
| Article | Year |
|---|---|
Combined Menin and EGFR Inhibitors Synergize to Suppress Colorectal Cancer via EGFR-Independent and Calcium-Mediated Repression of SKP2 Transcription.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Calcium; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inositol 1,4,5-Trisphosphate Receptors; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins; S-Phase Kinase-Associated Proteins; Thapsigargin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |